Alercell receives the Global Excellence Award for “Best for Innovative Oncology Testing Solutions 2023 – Montana”

Bozeman September 7th, 2023 - Alercell receives the Global Excellence Award for “Best for Innovative Oncology Testing Solutions 2023 – Montana” by GHP Global Health & Pharma. See: Alercell (2023 Winner: Global Excellence Awards) - GHP News (ghp-news.com)

Global Health & Pharma Magazine (GHP) was initially launched to act as an information sharing platform for those in the healthcare and pharmaceutical industries. Though it maintains this founding cornerstone, the magazine itself, with a circulation of 110,000 globally, has expanded in scope to magnify the work of those that are setting the pace and looking to change their respective sectors for the better.

Alercell gained notable recognition, particularly for its groundbreaking achievement with LenaQ51®, the pioneering Leukemia diagnostic test capable of detecting mutations in up to 51 genes associated with Leukemia.

ABOUT ALERCELL 

Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. Alercell is a true innovator, disruptor, and leader in the field of preventative oncology. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide. Alercell's mission is to make a difference in the fight against cancer by providing innovative and accurate diagnostic solutions that improve patient outcomes. 

The Alercell® mission is built on the foundation of “stopping it before it starts”. Our genetics-based testing is the first line of assault against cancer & leukemia and infectious diseases. 

For more information, please visit: www.alercell.com and www.Lenadx.com

 Alercell (2023 Winner: Global Excellence Awards) - GHP News (ghp-news.com)